Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 2, 2010, Pages 620-629

  Yin, Michael T ^a   McMahon, Don J ^a   Ferris, David C ^b   Zhang, Chiyuan A ^a   Shu, Aimee ^a   Staron, Ronald ^a   Colon, Ivelisse ^a   Laurence, Jeffrey ^c   Dobkin, Jay F ^a   Hammer, Scott M ^a   Shane, Elizabeth ^a  

^a Department of Medicine   (United States)

^b BRONX LEBANON HOSPITAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; ESTRONE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AFRICAN AMERICAN; ARTICLE; BONE MASS; BONE TURNOVER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRONE BLOOD LEVEL; FEMALE; FRACTURE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 76149121133     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0708     Document Type: Article

References (34)

1. Luther VP, Wilkin AM 2007 HIV infection in older adults. Clin Geriatr Med 23:567-583, vii
2. Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M, Bryant K, Justice AC 2007 Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 45:1593-1601
3. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, Huebner RE, Janoff EN, Justice AC, Kuritzkes D, Nayfield SG, Plaeger SF, Schmader KE, Ashworth JR, Campanelli C, Clayton CP, Rada B, Woolard NF, High KP 2008 Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 47:542-553
4. Carr A, Miller J, Eisman JA, Cooper DA 2001 Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 15:703-709
5. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S 2004 Reduced bone density in HIV-infected women. AIDS 18:475-483
6. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE 2000 Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14:F63-F67
7. Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, Stracke H, Bretzel RG 2003 Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 46:221-227
8. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J 2003 Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17:1917-1923
9. Knobel H, Guelar A, Vallecillo G, Nogués X, Díez A 2001 Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15:807-808
10. Brown TT, Qaqish RB 2006 Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20:2165-2174
11. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS 2007 Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21:617-623
12. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE 2006 HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 42:1014-1020
13. Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A, Keller MJ 2008 Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 19:913-918
14. Bolland MJ, Grey AB, Gamble GD, Reid IR 2007 Clinical review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 92:4522-4528
15. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR 2006 Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) 65:191-197
16. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M, Tebas P 2003 Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36:482-490
17. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA 2009 Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral Regimen. J Acquir Immune Defic Syndr 51:554-561
18. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, Enejosa J 2007 The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 8:164-172
19. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D 2009 Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23:817-824
20. Dolan SE, Kanter JR, Grinspoon S 2006 Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 91:2938-2945
21. Triant VA, Brown TT, Lee H, Grinspoon SK 2008 Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93:3499-3504
22. Centers for Disease Control and Prevention 2009 HIV/AIDS Surveillance Report, 2007. 19:1-63
23. Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, Manandhar M, Addesso V, Shane E 2005 Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 16:1345-1352
24. Kanis JA 2002 Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936
25. Black DM, Palermo L, Nevitt MC, Genant HK, Epstein R, San Valentin R, Cummings SR 1995 Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. J Bone Miner Res 10:890-902
26. Hertzler AA, Frary RB 1994 A dietary calcium rapid assessment method (RAM). Top Clin Nutr 9:76-85
27. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S 2008 International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 43:1115-1121
28. Suzuki N, Yano T, Nakazawa N, Yoshikawa H, Taketani Y 1995 A possible role of estrone produced in adipose tissues in modulating postmenopausal bone density. Maturitas 22:9-12
29. Aukrust P, Haug CJ, Ueland T, Lien E, Müller F, Espevik T, Bollerslev J, Frøland SS 1999 Decreased bone formative and enhanced resorptive markers inhumanimmunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 84:145-150
30. Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK 2001 Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab 86:2020-2026
31. Zamboni G, Antoniazzi F, Bertoldo F, Lauriola S, Antozzi L, Tatò L 2003 Altered bone metabolism in children infected with human immunodeficiency virus. Acta Paediatrica 92:12-16
32. Fakruddin JM, Laurence J 2003 HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor κB ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-γ/RANKL cross-talk. J Biol Chem 278:48251-48258
33. Jain RG, Lenhard JM 2002 Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 277:19247-19250
34. Wang MW, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, Teitelbaum SL, Ross FP 2004 The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 114:206-213